These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 5053732)

  • 1. Diphenylhydantoin and epilepsy management.
    Easton JD
    Ann Intern Med; 1972 Sep; 77(3):421-3. PubMed ID: 5053732
    [No Abstract]   [Full Text] [Related]  

  • 2. [5,5-Diphenylhydantoin (hydantoinal Polfa)].
    Pakszys W
    Neurol Neurochir Pol; 1973; 7(1):79-84. PubMed ID: 4570505
    [No Abstract]   [Full Text] [Related]  

  • 3. Inadequate serum levels after intramuscular administration of diphenylhydantoin.
    Wilensky AJ; Lowden JA
    Neurology; 1973 Mar; 23(3):318-24. PubMed ID: 4735182
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma diphenylhydantoin values after oral and intramuscular administration of diphenylhydantoin.
    Serrano EE; Roye DB; Hammer RH; Wilder BJ
    Neurology; 1973 Mar; 23(3):311-7. PubMed ID: 4735181
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: Bioavailability of drugs after intramuscular injection.
    Cameron JD; Hedley DW
    Lancet; 1975 Mar; 1(7908):700. PubMed ID: 47135
    [No Abstract]   [Full Text] [Related]  

  • 6. A method for shifting from oral to intramuscular diphenylhydantoin administration.
    Wilder BJ; Serrano EE; Ramsey E; Buchanan RA
    Clin Pharmacol Ther; 1974 Sep; 16(3):507-13. PubMed ID: 4411662
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy of seizures in children.
    Forman PM
    Am Fam Physician; 1974 Sep; 10(3):144. PubMed ID: 4213499
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral and intramuscular phenytoin.
    Wilder BJ; Ramsay RE
    Clin Pharmacol Ther; 1976 Mar; 19(3):360-4. PubMed ID: 770051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primidone, diphenylhydantoin and phenobarbital. Aspects of acute and chronic toxicity.
    Gallagher BB; Baumel IP; Mattson RH; Woodbury SG
    Neurology; 1973 Feb; 23(2):145-9. PubMed ID: 4734509
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of diphenylhydantoin.
    Simpson JF
    Ann Intern Med; 1973 Feb; 78(2):305-6. PubMed ID: 4683770
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined treatment of epileptics with phenobarbital and diphenylhydantoin in small doses versus separate treatment with large doses of either drug. A study of the clinical effects.
    Volanschi D; Pintilie C
    Neurol Psychiatr (Bucur); 1978; 16(4):259-69. PubMed ID: 741196
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacodynamic aspects of phenobarbital (PB) and diphenylhydantoin (DPH). Correlations with clinical findings].
    Denegri M; Luciano L
    Rev Neuropsychiatr Infant; 1972; 20(3):375-83. PubMed ID: 5055027
    [No Abstract]   [Full Text] [Related]  

  • 13. [Determination of serum levels of phenobarbital and diphenylhydantoin in the treatment of epilepsy].
    Benetello P; Testa G; Furlanut M
    Clin Ter; 1978 Apr; 85(1):11-8. PubMed ID: 657740
    [No Abstract]   [Full Text] [Related]  

  • 14. One daily dose of diphenylhydantoin (DPH) to patients with epilepsy.
    Strandjord RE; Johannessen SI
    Acta Neurol Scand Suppl; 1972; 51():499-500. PubMed ID: 4514392
    [No Abstract]   [Full Text] [Related]  

  • 15. [Monitoring plasma levels of some antiepileptic drugs (phenobarbital, diphenylhydantoin, carbamazepine) in the Lennox-Gastaut syndrome and in other forms of epilepsy (partial and secondary generalized) in childhood].
    Viani F; Gerna M; Riboldi A; Rossotti V; Morselli PL
    Riv Neurol; 1975; 45(2):189-98. PubMed ID: 809828
    [No Abstract]   [Full Text] [Related]  

  • 16. The relationship between the serum levels of phenobarbital and diphenylhydantoin and clinical data in patients with drug resistant epilepsy.
    Bendarzewska-Nawrocka B; Pietruszewska E; Bacia T
    Monogr Neural Sci; 1980; 5():229-34. PubMed ID: 7322157
    [No Abstract]   [Full Text] [Related]  

  • 17. [Plasma diphenylhydantoin concentration in epileptic patients].
    Herishanu Y; Eylath U
    Harefuah; 1974 Sep; 87(6):251-3. PubMed ID: 4442797
    [No Abstract]   [Full Text] [Related]  

  • 18. One daily dose of diphenylhydantoin for patients with epilepsy.
    Strandjord RE; Johannessen SI; Halpern LM
    Epilepsia; 1974 Sep; 15(3):317-27. PubMed ID: 4527914
    [No Abstract]   [Full Text] [Related]  

  • 19. Interrelation at plasmatic level between antiepileptic drugs and lipids. Its implications in the efficiency of treatment in epilepsy. II. Influence of some lipid changes upon treatment with phenobarbital or/and diphenylhydantoin.
    Rogozea R; Florea-Ciocoiu V; Bălăiţă C; Luca N
    Neurol Psychiatr (Bucur); 1981; 19(1):3-11. PubMed ID: 7221416
    [No Abstract]   [Full Text] [Related]  

  • 20. [Value of anticonvulsant level determination in the treatment of epilepsies].
    Loiseau P; Brachet-Liermain A; Legroux M; Jogeix M
    Nouv Presse Med; 1977 Mar; 6(10):813-7. PubMed ID: 322087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.